IPD strategy seen as key to supporting decision-making, PharmaLex survey finds

PharmaLex
August 11, 2022
8:00 am
Blog

Frédéric Pailloux, Senior Director and Global Head of Integrated Product Development Solution

An integrated product development (IPD) strategy is widely seen as a framework to support critical decisions related to timelines, competitiveness, regulatory pathways and market access. That’s one of the findings from a recent survey conducted by PharmaLex and Censuswide.

Most respondents (98%) say a key driver for implementing IPD is to support innovation across R&D as well as to gain better alignment on strategy. Team alignment, enabled through technology, is a core area of focus for those implementing IPD strategies, while a majority or organizations say they are managing IPD through a governance structure (56%).

While IPD strategies are gaining traction, there are challenges to overcome, in particular company culture, since it dictates how fast companies can respond to new opportunities, identify risks and set new courses. Download the survey report to learn more.

Disclaimer:

This blog is intended to communicate PharmaLex’s capabilities which are backed by the author’s expertise. However, PharmaLex US Corporation and its parent, Cencora, Inc., strongly encourage readers to review the references provided with this article and all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto as the article may contain certain marketing statements and does not constitute legal advice.